⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21170726 | 0.82 | — | — | |
| SCHEMBL9940115 | 0.77 | PTGS2 (0.42) | — | |
| SCHEMBL22175795 | 0.76 | GABRA1 (0.33) | — | |
| SCHEMBL12151300 | 0.73 | — | — | |
| SCHEMBL24801685 | 0.71 | — | — | |
| SCHEMBL16168829 | 0.71 | — | — | |
| SCHEMBL20375685 | 0.71 | — | — | |
| SCHEMBL27846156 | 0.71 | POLB (0.36) | — | |
| SCHEMBL14984921 | 0.68 | — | — | |
| SCHEMBL12151367 | 0.68 | SMYD3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023227666-A1 | PYRIMIDINONE COMPOUNDS FOR TREATING ACUTE INFLAMMATION | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | WO | disclosed |
| US-11780862-B2 | Inhibitors of MEK kinase | KINNATE BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11753395-B2 | Inhibitors of MET kinase | KINNATE BIOPHARMA INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11634384-B2 | Prodrugs of phenolic TRPV1 agonists | Concentric Analgesics, Inc. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11124537-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11110103-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210017220-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-10717712-B2 | Pegylated prodrugs of phenolic TRPV1 agonists | Concentric Analgesics, Inc. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20200031780-A1 | PEGYLATED PRODRUGS OF PHENOLIC TRPV1 AGONISTS | Concentric Analgesics, Inc. | 2020-01-30 | — | — | US | disclosed |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120015966-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2012-01-19 | — | — | US | disclosed |
| EP-2402318-A1 | DGAT inhibitors | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402320-A1 | Anorectic agents | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| WO-2011038261-A1 | HETEROCYCLIC KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20100292273-A1 | Cannabinoid Receptor Modulators | 7TM PHARMA A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| EP-1687292-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |